<DOC>
	<DOCNO>NCT01784068</DOCNO>
	<brief_summary>The main purpose study investigate whether nilotinib treatment safely suspend recurrence CML select patient respond optimally treatment</brief_summary>
	<brief_title>Nilotinib Treatment-free Remission Study CML ( Chronic Myeloid Leukemia ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Minimum 2 calendar year nilotinib treatment least last 12 month nilotinib treatment prior prescreening approve total dialy dose 600 mg BID reduce dose 400 mg QD require perspective tolerance BCRABL positive CML document chronic phase time diagnosis Evidence typical BCRABL transcript ( b3a2 and/or b2a2 ) time CMLCP diagnosis i.e . prior first start TKI treatment amenable standardized RTPCR quantification '' Patient MR4.5 prescreening Novartis designate lab ECOG performance status 02 Adequate end organ function define : Direct bilirubin ≤ 1.5 x ULN except ) patient document Gilbert 's syndrome bilirubin value allow ii ) patient asymptomatic hyperbilirubinemia ( liver transaminase alkaline phosphatase within normal range ) . SGOT ( AST ) SGPT ( ALT ) ≤ 3 x ULN i.e . equivalent ≤ Grade 1 NCICTCAE v.4.03 Serum lipase ≤ 2 x ULN i.e . equivalent ≤ Grade 2 NCICTCAE v.4.03 Alkaline phosphatase ≤ 2.5 x ULN Serum creatinine &lt; 1.5 x ULN Patients must follow electrolyte value within normal limit correct within normal limit supplement prior first dose study medication : Potassium ( suggest keep prevent issue QT and/or rhythm abnormality ) Magnesium ( suggest keep prevent issue QT and/or rhythm abnormality ) Total calcium ( correct serum albumin ) Patients must normal marrow function define : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 10E9/L Hemoglobin ≥ 9.0 g/dL Platelets ≥ 100 x 10E9/L Previous treatment BCRABL inhibitor nilotinib total cumulative duration 4 week Previous treatment alphainterferon duration Previous anticancer agent CML nilotinib except cytoreduction CML diagnosis 4 week first dose nilotinib Known second chronic phase CML previous progression AP/BC Poorly control diabetes mellitus ( define HbA1c &gt; 9 % ) Impaired cardiac function include one following : LVEF &lt; 45 % institutional low limit normal range ( whichever high ) Inability determine QT interval ECG , except patient evidence measurable QT interval time CML diagnosis ( e.g . prior first start TKI treatment ) document clinical sign cardiovascular disease and/or clinical sign conduction abnormality . Complete leave bundle branch block Right bundle branch block plus leave anterior posterior hemiblock Use ventricularpaced pacemaker Congenital long QT syndrome know family history long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia QTc &gt; 450 msec average three serial baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient retested QTc.This exclusion criterion applicable patient nonmeasurable QT interval evidence measurable QT interval time CML diagnosis ( e.g . prior first start TKI treatment ) document clinical sign cardiovascular disease and/or clinical sign conduction abnormality . History clinical sign myocardial infarction within 1 year study entry History unstable angina within 1 year study entry Other clinically significant heart disease ( e.g . congestive heart failure , cardiomyopathy uncontrolled hypertension ) History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis Known presence significant congenital acquire bleed disorder unrelated cancer History another active malignancy within 5 year prior study entry exception previous concomitant basal cell skin cancer previous carcinoma situ treat curatively Treatment investigational agent ( define use accordance approve indication ) within 4 week Day 1 Patients actively receive therapy strong CYP3A4 inhibitor and/or inducer , treatment either discontinue switched different medication prior start study drug . See Appendix 1 list medication . This list may exhaustive . Patients actively receive therapy herbal medicine strong CYP3A4 inhibitor and/or inducer , treatment either discontinue switched different medication prior start study drug . These herbal medicine may include Echinacea , ( include E. purpurea , E. angustifolia E. pallida ) , Piperine , Artemisinin , St. John 's Wort , Ginkgo . Patients currently receive treatment medication potential prolong QT interval treatment either safely discontinue switch different medication prior start study drug . ( Please see http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm list agent prolong QT interval ) Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception study 14 day final dose nilotinib . Highly effective contraception define either : Total abstinence ( line prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male sterilization ( least 6 month prior enrol ) . For female patient study vasectomized male partner sole partner patient . Use combination two following : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository In case use oral contraception woman stable pill minimum 3 month take study treatment Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior enrol . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . If study patient become pregnant suspect pregnant study within 30 day final dose nilotinib , Study Doctor need inform immediately ongoing study treatment nilotinib stop immediately . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ph+ CML-CP</keyword>
	<keyword>chronic phase</keyword>
	<keyword>nilotinib treatment</keyword>
	<keyword>2 year treatment</keyword>
	<keyword>MR 4.5</keyword>
	<keyword>Loss MR 4</keyword>
	<keyword>Loss MMR</keyword>
</DOC>